Please try another search
For the six months ended 30 April 2016, Agilent Technologies Inc revenues increased 3% to $2.05B. Net income before extraordinary items increased 16% to $214M. Revenues reflect Agilent CrossLab segment increase of 6% to $690M, Diagnostics and Genomics segment increase of 6% to $336M. Net income benefited from Ineffective G/L on Derivatives - Hedging increase from $17M (expense) to $3M (income).
Period Ending: | Apr 30, 2015 | Jan 31, 2015 | Oct 31, 2014 | Jul 31, 2014 |
---|---|---|---|---|
Total Revenue | 963 | 1026 | 1805 | 1766 |
Gross Profit | 480 | 513 | 897 | 914 |
Operating Income | 107 | 115 | 174 | 229 |
Net Income | 83 | 72 | 23 | 147 |
Period Ending: | Apr 30, 2015 | Jan 31, 2015 | Oct 31, 2014 | Jul 31, 2014 |
---|---|---|---|---|
Total Assets | 7412 | 7519 | 10831 | 10380 |
Total Liabilities | 3254 | 3282 | 5533 | 4743 |
Total Equity | 4158 | 4237 | 5298 | 5637 |
Period Ending: | Apr 30, 2015 | Jan 31, 2015 | Oct 31, 2014 | Jul 31, 2014 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | 163 | 790 | 711 | 547 |
Cash From Investing Activities | -38 | -31 | -230 | -172 |
Cash From Financing Activities | -929 | -828 | -97 | -658 |
Net Change in Cash | -831 | -100 | 353 | -284 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review